NEW YORK - Pfizer halted a late-stage study of its second-best selling drug, Lyrica, as a possible treatment for a nerve pain in HIV patients.
The world's largest drugmaker said Friday it was studying the drug in patients with HIV neuropathy, which is nerve damage characterized by burning pain that usually starts in the feet. An early analysis of study data showed that pain symptom improvements were nearly identical to those patients treated with a placebo.
No safety concerns were raised in the study, and Pfizer said it will continue to analyze the initial results.
Lyrica is already approved in the United States to treat diabetic nerve pain, pain after shingles, fibromyalgia and for some seizures in adults with epilepsy. It brought in $955 million in sales in the first quarter for the New York drugmaker, behind only cholesterol fighter Lipitor's $1.4 billion.
Pfizer lost the U.S. patent protecting Lipitor last fall, and Lyrica could overtake the drug to become Pfizer's top seller, especially after several generic drugmakers enter the market at the end of this month with their own versions of Lipitor.
Lyrica's revenue increased 16 percent in the recently completed first quarter, while Lipitor sales plunged 42 percent.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Indiana Gov. Mike Pence is expected to give some more details on the education proposals he wants legislators to approve during their upcoming session.
TV commercials and billboards are part of how local hospitals work to attract patients, but the facilities also are striving to bring back the patients who gave them a try.
Curt Hufty walked slowly through what remained of the former Flora train depot as he recounted the story.